A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Dupilumab (Primary) ; Calcineurin inhibitors; Corticosteroids
- Indications Prurigo nodularis
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTY-PN PRIME2; PRIME2
- Sponsors Sanofi; Sanofi-Aventis GmbH
- 01 May 2023 Results of pooled analysis (from two studies NCT04183335 and NCT04202679) assessing the effect of Dupilumab in patients with prurigo nodularis published in the Nature Medicine
- 21 Mar 2023 Results of pooled analysis from LIBERTY PN-PRIME and PRIME2, assessing proportion of patients achieving clinically meaningful improvement in these scores , presented at the American Academy of Dermatology annual Meeting 2023
- 21 Mar 2023 Results of pooled analysis ((N=311 from two studies NCT04183335/NCT04202679) assessing the psychometric properties of Sleep-NRS in adult patients with prurigo nodularis presented at the American Academy of Dermatology annual Meeting 2023